Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MESONASDAQ:TGTXNASDAQ:TLXNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMESOMesoblast$11.72-1.9%$11.78$5.78▼$22.00$1.50B2.5270,614 shs385,657 shsTGTXTG Therapeutics$34.36+2.3%$38.59$15.16▼$46.48$5.45B2.213.00 million shs1.92 million shsTLXTelix Pharmaceuticals Limited American Depositary Shares$16.68+2.6%$16.98$13.61▼$30.36$5.64BN/A27,012 shs11,042 shsVRNAVerona Pharma$71.31+2.6%$63.68$11.39▼$74.18$5.78B0.21.29 million shs914,905 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMESOMesoblast0.00%+6.84%+9.33%-34.53%+62.78%TGTXTG Therapeutics0.00%+2.14%-10.33%+11.89%+93.91%TLXTelix Pharmaceuticals Limited American Depositary Shares0.00%-2.91%-0.18%-2.97%+1,667,999,900.00%VRNAVerona Pharma0.00%+12.55%+21.03%+11.06%+411.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMESOMesoblast1.875 of 5 stars3.52.00.00.01.90.80.6TGTXTG Therapeutics3.9199 of 5 stars2.43.00.03.52.81.71.9TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/AN/AN/AN/AVRNAVerona Pharma3.2633 of 5 stars3.63.00.00.04.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMESOMesoblast 3.00Buy$18.0053.58% UpsideTGTXTG Therapeutics 2.80Moderate Buy$40.8018.74% UpsideTLXTelix Pharmaceuticals Limited American Depositary Shares 3.00Buy$22.0031.89% UpsideVRNAVerona Pharma 3.11Buy$81.5014.29% UpsideCurrent Analyst Ratings BreakdownLatest MESO, TGTX, TLX, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.004/30/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.004/28/2025VRNAVerona PharmaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy4/28/2025VRNAVerona PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$100.004/21/2025VRNAVerona PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$80.003/31/2025MESOMesoblastCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/12/2025TLXTelix Pharmaceuticals Limited American Depositary SharesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/4/2025MESOMesoblastCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/4/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.002/28/2025VRNAVerona PharmaRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$83.002/28/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $93.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMESOMesoblast$5.67M264.12N/AN/A$4.21 per share2.78TGTXTG Therapeutics$386.39M14.12$0.10 per share353.90$1.06 per share32.42TLXTelix Pharmaceuticals Limited American Depositary Shares$783.21M7.20N/AN/AN/A∞VRNAVerona Pharma$118.54M48.78N/AN/A$3.10 per share23.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)TGTXTG Therapeutics$12.67M$0.24N/A34.36N/A-5.42%-8.32%-3.40%8/5/2025 (Estimated)TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/A0.0034.75N/AN/AN/AN/AN/AVRNAVerona Pharma-$54.37M-$2.00N/A2,377.00N/AN/A-79.54%-43.49%N/ALatest MESO, TGTX, TLX, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million4/29/2025Q1 2025VRNAVerona Pharma-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million3/3/2025Q4 2024TGTXTG Therapeutics$0.08$0.15+$0.07$0.15$100.67 million$108.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMESOMesoblastN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMESOMesoblast0.211.181.18TGTXTG Therapeutics1.274.593.91TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AVRNAVerona Pharma0.9313.0312.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMESOMesoblast1.43%TGTXTG Therapeutics58.58%TLXTelix Pharmaceuticals Limited American Depositary SharesN/AVRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipMESOMesoblast18.80%TGTXTG Therapeutics10.64%TLXTelix Pharmaceuticals Limited American Depositary SharesN/AVRNAVerona Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMESOMesoblast80127.78 million103.17 millionOptionableTGTXTG Therapeutics290158.76 million139.32 millionOptionableTLXTelix Pharmaceuticals Limited American Depositary SharesN/A337.88 millionN/AN/AVRNAVerona Pharma3081.08 million76.10 millionOptionableMESO, TGTX, TLX, and VRNA HeadlinesRecent News About These CompaniesVerona Pharma plc (NASDAQ:VRNA) Receives Consensus Rating of "Buy" from AnalystsMay 18 at 1:57 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Stake Lifted by Parkman Healthcare Partners LLCMay 16 at 8:12 AM | marketbeat.comNicholas Investment Partners LP Invests $7.19 Million in Verona Pharma plc (NASDAQ:VRNA)May 16 at 7:11 AM | marketbeat.comNuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPDMay 16 at 6:17 AM | taiwannews.com.twVerona Pharma plc (NASDAQ:VRNA) Receives Average Rating of "Buy" from BrokeragesMay 16 at 1:59 AM | americanbankingnews.comOctagon Capital Advisors LP Sells 1,263,936 Shares of Verona Pharma plc (NASDAQ:VRNA)May 15 at 7:36 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Bought by Janus Henderson Group PLCMay 15 at 5:40 AM | marketbeat.comRaymond James Financial Inc. Invests $225,000 in Verona Pharma plc (NASDAQ:VRNA)May 15 at 3:06 AM | marketbeat.comWhy Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy NowMay 13, 2025 | insidermonkey.comFred Alger Management LLC Takes $1.34 Million Position in Verona Pharma plc (NASDAQ:VRNA)May 13, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Acquired by Barclays PLCMay 13, 2025 | marketbeat.comFindell Capital Management LLC Makes New $8.36 Million Investment in Verona Pharma plc (NASDAQ:VRNA)May 11, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Has $5.89 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)May 10, 2025 | marketbeat.comDeep Track Capital LP Sells 2,330,025 Shares of Verona Pharma plc (NASDAQ:VRNA)May 9, 2025 | marketbeat.comDuquesne Family Office LLC Purchases 201,535 Shares of Verona Pharma plc (NASDAQ:VRNA)May 9, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Insider Sells $1,014,158.88 in StockMay 9, 2025 | insidertrades.comWhat Makes Verona Pharma plc (VRNA) a Good Investment?May 8, 2025 | insidermonkey.comWhat Makes Verona Pharma plc (VRNA) a Good Investment?May 8, 2025 | msn.comCaxton Associates LP Acquires New Position in Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comBeverly Hills Private Wealth LLC Purchases Shares of 5,566 Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comAxa S.A. Sells 74,142 Shares of Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMESO, TGTX, TLX, and VRNA Company DescriptionsMesoblast NASDAQ:MESO$11.72 -0.23 (-1.92%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$11.77 +0.05 (+0.43%) As of 05/16/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.TG Therapeutics NASDAQ:TGTX$34.36 +0.77 (+2.29%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$33.92 -0.45 (-1.30%) As of 05/16/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX$16.68 +0.43 (+2.65%) Closing price 05/16/2025 03:59 PM EasternExtended Trading$16.68 0.00 (0.00%) As of 05/16/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.Verona Pharma NASDAQ:VRNA$71.31 +1.78 (+2.56%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$70.69 -0.62 (-0.87%) As of 05/16/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
